New malaria vaccine trial aims to block the parasite at multiple stages
NCT ID NCT06958198
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new malaria vaccine designed to target the parasite at different stages of its life cycle. Researchers will give the vaccine to 56 healthy adults (18-35 years) and children (5-17 months) in Burkina Faso to check its safety and how well it triggers an immune response. The goal is to find a vaccine that could better protect against malaria.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Institut de Recherche en Sciences de la Santé
RECRUITINGSiglé, Boulkiemdé Province, BP 7192 OUAGADOUGOU 03, BF, Burkina Faso
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill make your blood deadly to malaria mosquitoes?
- Can a new vaccine stop malaria in its tracks?
- Can a new malaria vaccine slash childhood cases? a massive real-world test seeks answers.
- One shot, six months of malaria shield? a new trial tests a powerful antibody in children
- School health rooms and trained teachers: a new hope for Zambia's children?
- Experimental malaria vaccine aims to block parasite growth